XNASMOLN
Market cap200mUSD
Dec 23, Last price
5.44USD
1D
7.09%
1Q
8.47%
IPO
-72.32%
Name
Molecular Partners AG
Chart & Performance
Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
IPO date
Oct 22, 2014
Employees
168
Domiciled in
CH
Incorporated in
CH
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 7,038 -96.29% | 189,556 1,931.68% | 9,330 -0.15% | |||||||
Cost of revenue | 115,623 | 123,320 | 128,342 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (108,585) | 66,236 | (119,012) | |||||||
NOPBT Margin | 34.94% | |||||||||
Operating Taxes | (1,240) | 2 | ||||||||
Tax Rate | ||||||||||
NOPAT | (108,585) | 67,476 | (119,014) | |||||||
Net income | (61,984) -152.59% | 117,853 -284.77% | (63,785) 1.63% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 31 | (381) | 51,493 | |||||||
BB yield | -0.03% | 0.19% | -8.66% | |||||||
Debt | ||||||||||
Debt current | 1,208 | 1,198 | 1,189 | |||||||
Long-term debt | 6,096 | 8,502 | 10,889 | |||||||
Deferred revenue | 3,637 | 6,925 | ||||||||
Other long-term liabilities | 5,063 | 2,552 | 6,739 | |||||||
Net debt | (179,585) | (239,444) | (120,735) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (59,005) | 118,566 | (90,953) | |||||||
CAPEX | (575) | (1,417) | (1,307) | |||||||
Cash from investing activities | 44,637 | (101,121) | (22,237) | |||||||
Cash from financing activities | (1,167) | (1,570) | 50,581 | |||||||
FCF | (107,031) | 68,387 | (117,773) | |||||||
Balance | ||||||||||
Cash | 186,889 | 249,144 | 132,813 | |||||||
Long term investments | ||||||||||
Excess cash | 186,537 | 239,666 | 132,346 | |||||||
Stockholders' equity | (188,120) | (125,157) | (247,721) | |||||||
Invested Capital | 373,264 | 371,362 | 373,858 | |||||||
ROIC | 18.11% | |||||||||
ROCE | 26.90% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 32,771 | 33,266 | 31,005 | |||||||
Price | 3.44 -44.16% | 6.16 -67.88% | 19.18 -7.57% | |||||||
Market cap | 112,731 -44.99% | 204,916 -65.54% | 594,679 14.63% | |||||||
EV | (66,854) | (34,528) | 473,944 | |||||||
EBITDA | (106,165) | 68,624 | (116,447) | |||||||
EV/EBITDA | 0.63 | |||||||||
Interest | 49 | 605 | 548 | |||||||
Interest/NOPBT | 0.91% |